Altimmune completes enrollment in phase 2 clinical trial of heptcell™, an immunotherapeutic for chronic hepatitis b

Gaithersburg, md., april 11, 2023 (globe newswire) -- altimmune, inc. (nasdaq: alt), a clinical-stage biopharmaceutical company (the company), today announced that it has completed enrollment in its phase 2 clinical trial of heptcell, an immunotherapeutic for the treatment of chronic hepatitis b (chb). with the achievement of this milestone, data readout is planned for the first quarter of 2024.
ALT Ratings Summary
ALT Quant Ranking